Pipeline. NervGen’s lead drug candidate, NVG-291, has potential to treat nervous system damage, whether as a result of injury or disease. It is a first-in-class therapeutic administered by injection under the skin. NVG-291 is currently in a Phase 1 clinical trial in healthy volunteers to evaluate safety, tolerability and metabolism.
Our pipeline We have an exciting and balanced pipeline underpinned by great science. Latest quarterly updates Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. 184 projects in our pipeline 17 new molecular entities in our late-stage pipeline 3 new molecular entities under review
According to the report entitled "Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023", the Global Antibody Drug ...
Akari Therapeutics, Plc recently announced it is prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), with Part A data expected in the first half of 2023, and to the promising pre-clinical program of PAS
Acasti intended the acquisition to position itself as a late-stage specialty pharma company and secured novel drug delivery technologies and a